Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
100%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
100%
Perioperative Period
100%
Prognostic Indicator
100%
Platelet-to-lymphocyte Ratio
100%
Recurrence-free Survival
80%
Hazard Ratio
60%
Overall Survival
60%
Perioperative Use
60%
Survival Prediction
40%
Surgical Resection
40%
Recurrence Rate
40%
95% Confidence Interval
40%
Multivariable
20%
Neutrophils
20%
Multivariate Analysis
20%
Inflammatory Process
20%
Prognostic Value
20%
Tumor Recurrence
20%
Overall Survival Rate
20%
Tumor-associated
20%
Curative Surgery
20%
Reduced Rate
20%
Perioperative Data
20%
Cox Proportional Hazards
20%
Hematological Markers
20%
Ratio Model
20%
Tumor Survival
20%
Inflammation Biomarkers
20%
Medicine and Dentistry
Platelet
100%
Non Small Cell Lung Cancer
100%
Nonsteroid Antiinflammatory Agent
100%
Perioperative Period
100%
Lymphocyte
100%
Overall Survival
80%
Recurrence Free Survival
80%
Hazard Ratio
60%
Biological Marker
20%
Neoplasm
20%
Cancer
20%
Survival Rate
20%
Retrospective Study
20%
Tumor Recurrence
20%
Drug Use
20%
Inflammation
20%
Neutrophil
20%
Multivariate Analysis
20%
Nursing and Health Professions
Perioperative
100%
Non Small Cell Lung Cancer
100%
Perioperative Period
100%
Nonsteroid Antiinflammatory Agent
100%
Platelet Lymphocyte Ratio
100%
Overall Survival
66%
Recurrence Free Survival
66%
Hazard Ratio
50%
Confidence Interval
33%
Neoplasm
16%
Survival Rate
16%
Biological Marker
16%
Inflammation
16%
Tumor Recurrence
16%
Drug Use
16%
Multivariate Analysis
16%
Neutrophil
16%